Merck's Winrevair reduced clinical worsening in PAH patients in the Phase 3 HYPERION trial, building on prior positive study ...

Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

RAHWAY, N.J., June 23, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR ...

US pharma giant Merck & Co today announced positive top-line results from the Phase III HYPERION study evaluating Winrevair ...

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

Merck, known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR™ versus placebo in recently diagnosed ...

Merck Announces Phase 3 HYPERION Study of WINREVAIR™ ... reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy.

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

Phase 3 study results evaluating sotatercept-csrk in recently diagnosed adults with pulmonary arterial hypertension were announced.

On day one of the highly anticipated first meeting of the CDC's newly formed vaccine advisory committee, members debated the ...

A few of the new members Health Secretary Robert F. Kennedy Jr. appointed to the federal panel have promoted misinformation ...

At the first meeting of a controversial new group of vaccine advisers to the US Centers for Disease Control and Prevention, ...